Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR)
CUSIP: 04683R106
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 79,671,812
- Total 13F shares
- 52,688,325
- Share change
- -183,834
- Total reported value
- $189,687,193
- Price per share
- $3.60
- Number of holders
- 105
- Value change
- -$496,611
- Number of buys
- 48
- Number of sells
- 36
Quarterly Holders Quick Answers
What is CUSIP 04683R106?
CUSIP 04683R106 identifies AVIR - Atea Pharmaceuticals, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 04683R106:
Top shareholders of AVIR - Atea Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.1%
from 13D/G
|
8,943,065
|
$26,739,765 | — | 31 Mar 2025 | |
| Jean-Pierre Sommadossi |
13D/G
|
— |
10%
|
8,876,453
|
$26,185,536 | $0 | 31 Mar 2025 | |
| BML Capital Management, LLC |
13F
|
Company |
9.6%
|
7,609,812
|
$22,753,338 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
7.6%
|
6,018,019
|
$17,993,878 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
6%
|
4,800,000
|
$14,352,000 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.9%
|
4,727,702
|
$14,135,829 | — | 31 Mar 2025 | |
| Bradley Louis Radoff |
13D/G
|
Radoff Bradley Louis |
4%
|
3,380,100
|
$9,971,295 | +$811,250 | 16 Apr 2025 | |
| EcoR1 Capital, LLC |
13D/G
|
— |
4%
|
3,341,653
|
$9,857,876 | $0 | 31 Dec 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
3.1%
|
2,485,638
|
$7,432,058 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.5%
|
1,977,337
|
$5,913,706 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
1,770,688
|
$5,294,357 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.6%
|
1,278,400
|
$3,822,416 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.5%
|
1,183,726
|
$3,538,970 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.2%
|
917,846
|
$2,743,000 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.97%
|
773,217
|
$2,311,919 | — | 31 Mar 2025 | |
| Almitas Capital LLC |
13F
|
Company |
0.9%
|
715,005
|
$2,137,865 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.87%
|
690,175
|
$2,063,623 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.76%
|
607,882
|
$1,817,567 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.73%
|
582,729
|
$1,742,359 | — | 31 Mar 2025 | |
| Newtyn Management, LLC |
13F
|
Company |
0.73%
|
580,000
|
$1,734,200 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.67%
|
533,000
|
$1,593,670 | — | 31 Mar 2025 | |
| Franklin M. Berger |
3/4/5
|
Director |
—
mixed-class rows
|
547,697
mixed-class rows
|
$1,526,418 | — | 20 Jun 2025 | |
| CM Management, LLC |
13F
|
Company |
0.63%
|
500,000
|
$1,495,000 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.57%
|
455,344
|
$1,361,481 | — | 31 Mar 2025 | |
| Peapod Lane Capital LLC |
13F
|
Company |
0.57%
|
452,060
|
$1,351,659 | — | 31 Mar 2025 | |
| BANQUE PICTET & CIE SA |
13F
|
Company |
0.43%
|
345,077
|
$1,031,780 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.43%
|
344,545
|
$1,030,189 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.38%
|
304,530
|
$910,545 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.37%
|
291,091
|
$870,363 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.32%
|
258,608
|
$773,238 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.32%
|
251,749
|
$752,730 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
203,116
|
$607,317 | — | 31 Mar 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.25%
|
201,233
|
$603,699 | — | 31 Mar 2025 | |
| Auour Investments LLC |
13F
|
Company |
0.22%
|
177,000
|
$522,150 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.22%
|
173,156
|
$517,736 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.22%
|
171,312
|
$512,224 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.2%
|
162,861
|
$486,954 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
143,100
|
$427,869 | — | 31 Mar 2025 | |
| Bruno Lucidi |
3/4/5
|
Director |
—
mixed-class rows
|
153,950
mixed-class rows
|
$419,989 | — | 20 Jun 2025 | |
| Bruce Polsky |
3/4/5
|
Director |
—
mixed-class rows
|
136,406
mixed-class rows
|
$385,928 | — | 20 Jun 2025 | |
| Polly A. Murphy |
3/4/5
|
Director |
—
mixed-class rows
|
127,245
mixed-class rows
|
$360,186 | — | 20 Jun 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.15%
|
119,220
|
$356,468 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.15%
|
118,167
|
$353,319 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.15%
|
116,443
|
$348,153 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.13%
|
105,584
|
$315,696 | — | 31 Mar 2025 | |
| STRS OHIO |
13F
|
Company |
0.13%
|
105,500
|
$315,445 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.13%
|
102,607
|
$306,795 | — | 31 Mar 2025 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.12%
|
98,127
|
$293,400 | — | 31 Mar 2025 | |
| Barbara Gayle Duncan |
3/4/5
|
Director |
—
mixed-class rows
|
103,950
mixed-class rows
|
$279,489 | — | 20 Jun 2025 | |
| Jerome M. Adams |
3/4/5
|
Director |
—
mixed-class rows
|
103,950
mixed-class rows
|
$279,489 | — | 20 Jun 2025 |
Institutional Holders of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) as of Q2 2025
As of 30 Jun 2025,
Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) was held by
105 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,688,325 shares.
The largest 10 holders included
BlackRock, Inc., BML Capital Management, LLC, FMR LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, DIMENSIONAL FUND ADVISORS LP, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
105
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
102
Q2 2025 holders
105
Holder diff
3
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.